ReShape Lifesciences Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 8.68 million compared to USD 11.24 million a year ago. Net loss was USD 11.39 million compared to USD 46.21 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2549 USD | +1.92% | +35.59% | +2.08% |
May. 15 | ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 15 | Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.08% | 5.98M | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.61B |
- Stock Market
- Equities
- RSLS Stock
- News ReShape Lifesciences Inc.
- ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023